2hdl: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Solution structure of Brak/CXCL14== | ==Solution structure of Brak/CXCL14== | ||
<StructureSection load='2hdl' size='340' side='right'caption='[[2hdl | <StructureSection load='2hdl' size='340' side='right'caption='[[2hdl]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2hdl]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[2hdl]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2HDL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2HDL FirstGlance]. <br> | ||
</td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2hdl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2hdl OCA], [https://pdbe.org/2hdl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2hdl RCSB], [https://www.ebi.ac.uk/pdbsum/2hdl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2hdl ProSAT]</span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2hdl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2hdl OCA], [https://pdbe.org/2hdl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2hdl RCSB], [https://www.ebi.ac.uk/pdbsum/2hdl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2hdl ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/CXL14_HUMAN CXL14_HUMAN] Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays.<ref>PMID:10049774</ref> <ref>PMID:10946286</ref> | |||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
| Line 35: | Line 34: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Harder | [[Category: Harder AG]] | ||
[[Category: Peterson | [[Category: Peterson FC]] | ||
[[Category: Schwarze | [[Category: Schwarze SR]] | ||
[[Category: Thorpe | [[Category: Thorpe JA]] | ||
[[Category: Volkman | [[Category: Volkman BF]] | ||
Revision as of 11:26, 14 June 2023
Solution structure of Brak/CXCL14Solution structure of Brak/CXCL14
Structural highlights
FunctionCXL14_HUMAN Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays.[1] [2] Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedThe chemokine CXCL14/BRAK participates in immune surveillance by recruiting dendritic cells. CXCL14 gene expression is altered in a number of cancers, but protein expression levels have not been investigated. Here we report that CXCL14 protein can be expressed in primary epithelial cells; however, in several immortalized and cancer cell lines this protein is targeted for polyubiquitylation and proteasomal degradation. We determined the NMR structure of CXCL14 to identify motifs controlling its expression. CXCL14 adopts the canonical chemokine tertiary fold but contains a unique five amino acid insertion (41VSRYR45) relative to other CXC chemokines. Deletion or substitution of key residues within this insertion prevented proteasomal degradation. Furthermore, we defined a 15 amino acid fragment of CXCL14 that is sufficient to induce proteasomal degradation. This study elucidates a post-translational mechanism for the loss of CXCL14 in cancer and a novel mode of chemokine regulation. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome.,Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR J Mol Biol. 2006 Nov 3;363(4):813-22. Epub 2006 Aug 26. PMID:16987528[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||